Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE...
Gespeichert in:
| Veröffentlicht in: | SpringerPlus 2016-09, Vol.5 (1), p.1569-1569, Article 1569 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1569 |
|---|---|
| container_issue | 1 |
| container_start_page | 1569 |
| container_title | SpringerPlus |
| container_volume | 5 |
| creator | Peng, Qin Li, Kang Cao, Ming Rong Bie, Cai Qun Tang, Hui Jun Tang, Shao Hui |
| description | Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE, WANFANG, and CNKI were retrieved to identify eligible studies. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated using random or fixed models. A total of six RCTs including 1100 adult patients with CHC met the inclusion criteria and the patients were infected with HCV genotype 1–4, with the genotype 1 infection accounting for 73.1 %. Meta-analysis showed daclatasvir-based combination therapy yielded a significantly higher probability of achieving the overall RVR (46.43 vs. 18.97 %) with pooled RR of 3.77 (95 % CI 1.95–7.28,
p
|
| doi_str_mv | 10.1186/s40064-016-3218-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5023653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1822468513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-34d8a726d52c3bdadbb04b5afc5e177b0ab2e79cf4bdf0a54d94ffe749c7a4233</originalsourceid><addsrcrecordid>eNp9kc9uVCEUh4mxsU3bB3BjWLqhBS73z7gwMaNWkyZudE0O3MNcmnthBKa2j-WL9JlkMrWpG9lAcr7zOyd8hLwW_EKIobvMivNOMS461kgxsLsX5ESKVcPEwMXLZ-9jcp7zDa-n64Xq-StyLPuulULJE5I-gp2hQL71idq4GB9wpL98megWNz4UTA5TDOzhN4Uw0uQNVNQH6mKiZUJaEkJZMBQaHbVTZb2lE26h-OIzXb-jQBcswCDAfJ99PiNHDuaM54_3Kfnx-dP39Rd2_e3q6_rDNbNKycIaNQ7Qy25spW3MCKMxXJkWnG1R9L3hYCT2K-uUGR2HVo0r5Rz2amV7ULJpTsn7Q-52ZxYcbV0xway3yS-Q7nUEr_-tBD_pTbzVLZdN1-4D3j4GpPhzh7noxWeL8wwB4y5rMUipuqEVe1QcUJtizgnd0xjB9V6XPujSVZfe69J3tefN8_2eOv7KqYA8ALmWwgaTvom7VH8x_yf1D9YepSs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1822468513</pqid></control><display><type>article</type><title>Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis</title><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Peng, Qin ; Li, Kang ; Cao, Ming Rong ; Bie, Cai Qun ; Tang, Hui Jun ; Tang, Shao Hui</creator><creatorcontrib>Peng, Qin ; Li, Kang ; Cao, Ming Rong ; Bie, Cai Qun ; Tang, Hui Jun ; Tang, Shao Hui</creatorcontrib><description>Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE, WANFANG, and CNKI were retrieved to identify eligible studies. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated using random or fixed models. A total of six RCTs including 1100 adult patients with CHC met the inclusion criteria and the patients were infected with HCV genotype 1–4, with the genotype 1 infection accounting for 73.1 %. Meta-analysis showed daclatasvir-based combination therapy yielded a significantly higher probability of achieving the overall RVR (46.43 vs. 18.97 %) with pooled RR of 3.77 (95 % CI 1.95–7.28,
p
< 0.0001) and a slightly higher probability of achieving the overall SVR
24
(65.08 vs. 47.77 %) with pooled RR of 1.41 (95 % CI 1.18–1.68,
p
< 0.0001), and did not show increased adverse events compared with the pegIFN-α/RBV regimen (control group). Subgroup analysis showed the rate of RVR and SVR
24
in high-dose daclatasvir (60 mg/day) group were slightly higher than the overall results; the rate of RVR in low-dose daclatasvir (10 mg/day) group was also higher than the control group, but its SVR
24
rate was similar between the two groups. Daclatasvir combined with pegIFN-α/RBV is effective and safe in treating adult patients with CHC, especially HCV genotype 1 infection, and daclatasvir (60 mg/day) is a better choice as compared with daclatasvir (10 mg/day).</description><identifier>ISSN: 2193-1801</identifier><identifier>EISSN: 2193-1801</identifier><identifier>DOI: 10.1186/s40064-016-3218-x</identifier><identifier>PMID: 27652142</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Humanities and Social Sciences ; Medicine ; multidisciplinary ; Review ; Science ; Science (multidisciplinary)</subject><ispartof>SpringerPlus, 2016-09, Vol.5 (1), p.1569-1569, Article 1569</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-34d8a726d52c3bdadbb04b5afc5e177b0ab2e79cf4bdf0a54d94ffe749c7a4233</citedby><cites>FETCH-LOGICAL-c442t-34d8a726d52c3bdadbb04b5afc5e177b0ab2e79cf4bdf0a54d94ffe749c7a4233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023653/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023653/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,41118,42187,51574,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27652142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Qin</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Cao, Ming Rong</creatorcontrib><creatorcontrib>Bie, Cai Qun</creatorcontrib><creatorcontrib>Tang, Hui Jun</creatorcontrib><creatorcontrib>Tang, Shao Hui</creatorcontrib><title>Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis</title><title>SpringerPlus</title><addtitle>SpringerPlus</addtitle><addtitle>Springerplus</addtitle><description>Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE, WANFANG, and CNKI were retrieved to identify eligible studies. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated using random or fixed models. A total of six RCTs including 1100 adult patients with CHC met the inclusion criteria and the patients were infected with HCV genotype 1–4, with the genotype 1 infection accounting for 73.1 %. Meta-analysis showed daclatasvir-based combination therapy yielded a significantly higher probability of achieving the overall RVR (46.43 vs. 18.97 %) with pooled RR of 3.77 (95 % CI 1.95–7.28,
p
< 0.0001) and a slightly higher probability of achieving the overall SVR
24
(65.08 vs. 47.77 %) with pooled RR of 1.41 (95 % CI 1.18–1.68,
p
< 0.0001), and did not show increased adverse events compared with the pegIFN-α/RBV regimen (control group). Subgroup analysis showed the rate of RVR and SVR
24
in high-dose daclatasvir (60 mg/day) group were slightly higher than the overall results; the rate of RVR in low-dose daclatasvir (10 mg/day) group was also higher than the control group, but its SVR
24
rate was similar between the two groups. Daclatasvir combined with pegIFN-α/RBV is effective and safe in treating adult patients with CHC, especially HCV genotype 1 infection, and daclatasvir (60 mg/day) is a better choice as compared with daclatasvir (10 mg/day).</description><subject>Humanities and Social Sciences</subject><subject>Medicine</subject><subject>multidisciplinary</subject><subject>Review</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><issn>2193-1801</issn><issn>2193-1801</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kc9uVCEUh4mxsU3bB3BjWLqhBS73z7gwMaNWkyZudE0O3MNcmnthBKa2j-WL9JlkMrWpG9lAcr7zOyd8hLwW_EKIobvMivNOMS461kgxsLsX5ESKVcPEwMXLZ-9jcp7zDa-n64Xq-StyLPuulULJE5I-gp2hQL71idq4GB9wpL98megWNz4UTA5TDOzhN4Uw0uQNVNQH6mKiZUJaEkJZMBQaHbVTZb2lE26h-OIzXb-jQBcswCDAfJ99PiNHDuaM54_3Kfnx-dP39Rd2_e3q6_rDNbNKycIaNQ7Qy25spW3MCKMxXJkWnG1R9L3hYCT2K-uUGR2HVo0r5Rz2amV7ULJpTsn7Q-52ZxYcbV0xway3yS-Q7nUEr_-tBD_pTbzVLZdN1-4D3j4GpPhzh7noxWeL8wwB4y5rMUipuqEVe1QcUJtizgnd0xjB9V6XPujSVZfe69J3tefN8_2eOv7KqYA8ALmWwgaTvom7VH8x_yf1D9YepSs</recordid><startdate>20160915</startdate><enddate>20160915</enddate><creator>Peng, Qin</creator><creator>Li, Kang</creator><creator>Cao, Ming Rong</creator><creator>Bie, Cai Qun</creator><creator>Tang, Hui Jun</creator><creator>Tang, Shao Hui</creator><general>Springer International Publishing</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160915</creationdate><title>Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis</title><author>Peng, Qin ; Li, Kang ; Cao, Ming Rong ; Bie, Cai Qun ; Tang, Hui Jun ; Tang, Shao Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-34d8a726d52c3bdadbb04b5afc5e177b0ab2e79cf4bdf0a54d94ffe749c7a4233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Humanities and Social Sciences</topic><topic>Medicine</topic><topic>multidisciplinary</topic><topic>Review</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Qin</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Cao, Ming Rong</creatorcontrib><creatorcontrib>Bie, Cai Qun</creatorcontrib><creatorcontrib>Tang, Hui Jun</creatorcontrib><creatorcontrib>Tang, Shao Hui</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>SpringerPlus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Qin</au><au>Li, Kang</au><au>Cao, Ming Rong</au><au>Bie, Cai Qun</au><au>Tang, Hui Jun</au><au>Tang, Shao Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis</atitle><jtitle>SpringerPlus</jtitle><stitle>SpringerPlus</stitle><addtitle>Springerplus</addtitle><date>2016-09-15</date><risdate>2016</risdate><volume>5</volume><issue>1</issue><spage>1569</spage><epage>1569</epage><pages>1569-1569</pages><artnum>1569</artnum><issn>2193-1801</issn><eissn>2193-1801</eissn><abstract>Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE, WANFANG, and CNKI were retrieved to identify eligible studies. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated using random or fixed models. A total of six RCTs including 1100 adult patients with CHC met the inclusion criteria and the patients were infected with HCV genotype 1–4, with the genotype 1 infection accounting for 73.1 %. Meta-analysis showed daclatasvir-based combination therapy yielded a significantly higher probability of achieving the overall RVR (46.43 vs. 18.97 %) with pooled RR of 3.77 (95 % CI 1.95–7.28,
p
< 0.0001) and a slightly higher probability of achieving the overall SVR
24
(65.08 vs. 47.77 %) with pooled RR of 1.41 (95 % CI 1.18–1.68,
p
< 0.0001), and did not show increased adverse events compared with the pegIFN-α/RBV regimen (control group). Subgroup analysis showed the rate of RVR and SVR
24
in high-dose daclatasvir (60 mg/day) group were slightly higher than the overall results; the rate of RVR in low-dose daclatasvir (10 mg/day) group was also higher than the control group, but its SVR
24
rate was similar between the two groups. Daclatasvir combined with pegIFN-α/RBV is effective and safe in treating adult patients with CHC, especially HCV genotype 1 infection, and daclatasvir (60 mg/day) is a better choice as compared with daclatasvir (10 mg/day).</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27652142</pmid><doi>10.1186/s40064-016-3218-x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2193-1801 |
| ispartof | SpringerPlus, 2016-09, Vol.5 (1), p.1569-1569, Article 1569 |
| issn | 2193-1801 2193-1801 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5023653 |
| source | PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Humanities and Social Sciences Medicine multidisciplinary Review Science Science (multidisciplinary) |
| title | Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T12%3A39%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Daclatasvir%20combined%20with%20peginterferon-%CE%B1%20and%20ribavirin%20for%20the%20treatment%20of%20chronic%20hepatitis%20C:%20a%20meta-analysis&rft.jtitle=SpringerPlus&rft.au=Peng,%20Qin&rft.date=2016-09-15&rft.volume=5&rft.issue=1&rft.spage=1569&rft.epage=1569&rft.pages=1569-1569&rft.artnum=1569&rft.issn=2193-1801&rft.eissn=2193-1801&rft_id=info:doi/10.1186/s40064-016-3218-x&rft_dat=%3Cproquest_pubme%3E1822468513%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1822468513&rft_id=info:pmid/27652142&rfr_iscdi=true |